1 / 6

Duchenne Muscular Dystrophy, Opportunity and Market Analysis

RnRMarketResearch adds ‘OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019’ to its store. Duchenne muscular dystrophy (DMD) is a rare genetic disorder affecting approximately 1 in 3,500 newborn boys and is characterized by progressive muscle degeneration, loss of ambulation, and death by the late 20s.

Rudraksha123
Download Presentation

Duchenne Muscular Dystrophy, Opportunity and Market Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019 By RnRMarketResearch Publisher Name : Global Markets Direct Date: 01-Apr-2015 No. of pages: 154 Single User License: US $7995 Browse more reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019 There are no marketed pharmacological therapies that are indicated for DMD. The current standard of care treatment involves generic corticosteroids which are used to marginally prolong muscle function but do not offer preventative treatment. The anticipated launch of PTC Therapeutics' Translarna in 2015 in the US and 5EU, followed by the 6MM launch of Exon-skipping therapies- BioMarin/Prosensa'sdrisapersen and Sarepta Therapeutics' eteplirsen, in 2015 and 2016, respectively, are set to change the treatment landscape and drive growth in the DMD market. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019 Key Questions Answered: How will the DMD market landscape change within the 2014-2019 forecast periods in the 6MM What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the DMD market How do the clinical and commercial attributes of late-stage pipeline drugs compare to one another and against existing treatment options Which patient population(s) are most likely to be targeted by late-stage pipeline drugs ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019 Scope: • Overview of DMD, including epidemiology, etiology, pathophysiology, symptoms and current treatment options • Annualized DMD therapeutics market revenue, annual cost of therapies and forecasts for five years to 2019. • Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the DMD therapeutics market. • Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including nonsense mutation readthrough inducer, exon-skipping therapies, synthetic electron transporter, PDE5 inhibitor. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019 Reasons to Buy: • Identify the unmet needs and remaining opportunities in the DMD therapeutics market. • Develop business strategies by understanding the trends shaping and driving the US and five major EU DMD therapeutics market. • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. • Assess the clinical and commercial viability of promising pipeline products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related